Overview

5 out of 5 (7 Reviews)

Credits

1.00

Post Assessment Questions

6

Start Date

1 Sep 2023

Last Review Date

14 Feb 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Ibutilide is a class III antiarrhythmic medication approved by the US Food and Drug Administration (FDA) for converting acute atrial flutter and atrial fibrillation to normal sinus rhythm. Studies indicate ibutilide's greater efficacy in treating atrial flutter than atrial fibrillation. In addition to its FDA-approved indications, ibutilide is commonly used off-label as a pretreatment for electro-cardioversion and may also be administered post-cardioversion to prevent recurrent atrial fibrillation. Moreover, ibutilide administration might be necessary following surgery. Ibutilide functions as a potassium channel blocker, extending phase 3 of the cardiac action potential. This leads to heightened refractoriness of atrial and ventricular myocytes, along with the atrioventricular node and the His-Purkinje system.

This activity comprehensively explores ibutilide's indications, mechanism of action, adverse event profile, pharmacological properties, essential monitoring, and drug interactions to ensure its safe and effective utilization in clinical settings. The knowledge gained from this activity helps establish the competency of the interprofessional healthcare team in proficiently managing cardiac disorders responsive to this therapeutic approach, thereby optimizing patient outcomes. Moreover, this activity also allows the healthcare team to make informed decisions in managing acute atrial arrhythmias by providing them with the necessary tools to tailor treatment strategies and mitigate potential risks, thereby fostering a collaborative approach to managing cardiac conditions.


UAN: JA4008338-0000-23-2366-H01-P

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the FDA-approved indications for ibutilide, such as managing acute atrial flutter and atrial fibrillation, as well as off-label uses, including pretreatment for electro-cardioversion and post-cardioversion therapy.

  • Screen patients for contraindications to ibutilide therapy, including hypersensitivity reactions and underlying cardiac conditions such as long QT syndrome.

  • Apply evidence-based guidelines and recommendations when selecting ibutilide as part of a comprehensive management approach for atrial flutter and fibrillation.

  • Coordinate with other healthcare providers to ensure continuity of care for patients receiving ibutilide, including transitions between inpatient and outpatient settings.

Pharmacy Activity Type:
Disease/Drug Therapy Related


Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Pharmacists: StatPearls, LLC designates this activity for a maximum of 1.00 ACPE credit(s). (UAN: JA4008338-0000-23-2366-H01-P ). Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Kristen C. on 4/10/2023

larry I. on 9/2/2023

Valentine C. on 9/22/2023

Craig T. on 11/9/2023

James L. on 12/11/2023

Jagan A. on 12/29/2023

James L. on 1/4/2024

Unlimited Pharmacist CE

Stay up to date on the latest medical knowledge with 6673 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7924.5 hours of CE.

Single Activity

Take this single activity

$29 1 activity

6 Month Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$119 per half year per user

1 Year Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$199 per 1 year per user